Andrew Moreno

DocwireNews

Among patients with myelodysplastic syndromes (MDS), red blood cell transfusion dependency negatively affects overall survival (OS) in those with higher risk disease as defined by the Molecular International Prognostic Scoring System (IPSS-M). This is according to a research team’s study findings presented at the 66th American Society of Hematology Annual Meeting &amp; Exposition in San Diego, California.
“Since therapeutic approaches are based on the initial risk assessment, including transfusion dependency status in this stratification can provide more accurate prognostic information that might potentially impact on the treatment strategy,” wrote lead author Elena Bechtold Javier, MD, of Bellvitge Biomedical Research Institute, Barcelona, Spain.
The researchers could not confirm from their study if in lower risk IPSS-M MDS there was such a relationship between transfusion dependency and OS. They noted that a larger study is necessary to validate their findings.
The cohort in the presented study comprised 214 patients with MDS or myelodysplastic chronic myelomonocytic leukemia from 13 centers. The patients had a mean age at diagnosis of 69 years, and 57.9% were men.
The researchers organized the patients into two categories of low- versus high-risk MDS: 29.9% of patients had “low-risk” disease, defined according to IPSS-M as very-low, low, or low-intermediate risk disease; and 70.1% had “high-risk” disease, defined as IPSS-M high-intermediate, high, or very-high risk disease.
Transfusion dependency, defined as receiving at least one red blood cell transfusion every eight weeks for four months, was present in 58.4% of the cohort. Dependency was present in 17.1% of patients in the study’s low-risk disease category and in 76% of patients in the high-risk disease category.
For the surviving patients in the cohort, the median follow-up was 19.4 months. The median OS in the low-risk MDS category was 10.4 years, and in the high-risk MDS category, median OS was 1.6 years (P&lt;.001). Among transfusion-dependent patients, the median OS was 1.49 years, and among nondependent patients, it was not reached (P&lt;.001).
In the low-risk MDS category, the researchers found no differences in OS between transfusion-dependent and nondependent patients. In the high-risk MDS category, transfusion-dependent patients had lower median OS than nondependent patients, at 1.31 years; median OS was not reached in the group of nondependent patients (P&lt;.001).
Multivariate analysis the researchers performed showed that age at diagnosis, high-risk disease, and transfusion dependency at diagnosis were independent factors of shorter OS.
Reference
Bechtold Javier E, Pomares H, Castaño-Díez S, et al. Impact of transfusion dependency on patients diagnosed with myelodysplastic syndrome according to IPSS-M risk group. Abstract #1838. Presented at the 66th American Society of Hematology Annual Meeting and Exposition; December 7-10, 2024; San Diego, California.

Emily Menendez

Higher ADR Linked to Lower Incidence of CRC Post-Colonoscopy

Colorectal Cancer

Real-World Data Study Gauges Survival Benefit from MDS Targeted Therapies by Mutation Type

ASH 2024

RBC Transfusion Dependency Linked to Reduced Overall Survival in Higher-Risk MDS

Latest News

Researchers noted that confirmation of this relationship in lower-risk disease would require a larger study.

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe